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Background. There remains controversy on the routine use of chemotherapy in localized SS. Methods. The records of 87 adult (AP)
and 15 pediatric (PP) patients with localized SS diagnosed between 1986 and 2007 at 2 centres in Toronto were reviewed. Results.
Median age for AP and PP was 37.6 (range 15–76) and 14 (range 0.4–18) years, respectively. 65 (64%) patients had large tumours
(>5cm). All patients underwent en bloc surgical resection resulting in 94 (92.2%) negative and 8 (7.8%) microscopically positive
surgical margins. 72 (82.8%) AP and 8 (53%) PP received radiotherapy. Chemotherapy was administered to 12 (13.8%) AP and
13 (87%) PP. 10AP and 5PP were evaluable for response to neoadjuvant chemotherapy, with response rate of 10% and 40%,
respectively. 5-year EFS and OS was 69.3 ± 4.8% and 80.3 ± 4.3%, respectively, and was similar for AP and PP, In patients with
tumors>5cm,inwhomchemotherapymightbeconsideredmostappropriate,relapse occurred in9/19(47%)withchemotherapy,
compared to 17/46 (37%) In those without. Conclusions. Patients with localized SS have a good chance of cure with surgery and
RT. Evidence for a well-deﬁned role of chemotherapy to improve survival In localized SS remains elusive.
1.Introduction
Synovial sarcoma (SS) accounts for approximately 8% of
all soft tissue sarcoma (STS) and is more common in
adolescents and young adults compared to older individuals
[1]. Prognostic factors associated with survival include
tumor size [2–7], tumor invasiveness [3–5], stage [5, 7],
tumor location [8, 9], histological subtype and grade [3,
7, 9, 10], and incomplete resection as manifested by the
pathological resection margin status [11]. Of these, tumour
size (greater or less than 5cm) is the most consistently
signiﬁcantprognosticfactorinpatientswithlocalizeddisease
[2–7]. Patient age has also been identiﬁed as a prognostic
factor [7,9].SimilartootherSTSlocalmanagement foradult
patients with localized SS is complete tumour resection,
often in combination with either adjuvant or neo-adjuvant
radiotherapy. With this approach, the 5-year overall survival
approaches 80% in some series [5]. Evidence of a well-
deﬁnedroleforchemotherapyremainsuncertain inlocalized
adult STS, but is more debatable in SS. Some series of
SS support a survival beneﬁt with chemotherapy [12–14],
while others have reached the opposite conclusion [15–18].
Pediatric experience with chemotherapy in SS demonstrates
response rates ranging from 37–56%, potentially justifying2 Sarcoma
its use [5, 19]. In the current study, we investigated the
impact of chemotherapy on survival in both pediatric and
adult patients with localized SS treated at two specialized
sarcoma centers.
2.Materialsand Methods
Between 1986 and 2007, a total of 102 consecutive patients
(87 adult and 15 pediatric) with localized SS were treated at
the joint Mount Sinai Hospital/Princess Margaret Hospital
Sarcoma Program (adult patients) and The Hospital for Sick
Children(pediatric patients), Toronto, ON,Canada. Patients
included in this study received all deﬁnitive sarcoma therapy
(surgery, chemotherapy, and/or radiation therapy) at the
two respective institutions. Patients were included in the
study if they presented with a localized primary malignancy
with no evidence of lung metastases and had not previously
receivedanytumourtherapy.Afterinstitutionalreviewboard
approval, medical records at each center were reviewed and
data on age at diagnosis, tumor-speciﬁc data (histology, size
(<5cmor≥5cm), location, depth, grade, surgical margins,
and lymph node status), therapy (chemotherapy, radiation,
and surgery), and clinical outcome were collected. Both
pediatric and adult patients had cross-sectional imaging of
theirprimary tumour(most commonlyMRI)as well aschest
imaging(mostcommonlyCTscanofthechest).Atumorwas
considered as invading bone or neurovascular structures if
there was either gross or microscopic invasion at pathologic
examination. Information on speciﬁc histological subtype
was not available for many cases and thus is not included
in this paper. Response to chemotherapy was assessed using
RECIST criteria [20] in those patients who had both pre-
and postchemotherapy MRI or CT scans performed prior to
surgery and preoperative radiotherapy, if it was utilized. The
total number of cycles of chemotherapy administered prior
to re-evaluation varied between patients.
All adult and pediatric patients underwent deﬁnitive sur-
gical resection. The delivery of radiotherapy and chemother-
apy varied between the adult and pediatric hospitals, but
was determined at a multidisciplinary sarcoma tumor board
conference. During the course of this study, if an adult
patient was treated with preoperative radiotherapy, 50Gy
in 2Gy daily fractions was administered. Until the year
2000, there was an additional possibility for a 16Gy in 2Gy
per fraction postoperative boost if the surgical resection
margins were positive. Patients treated with postoperative
radiotherapy received 66Gy. Radiation was generally utilized
when wide surgical resection margins were not attainable
[21]. In children, radiotherapy was reserved for those cases
with microscopic positive margins. In adults, the majority
of chemotherapy included both doxorubicin and ifosfamide,
whereas the protocol was more varied in children.
2.1. Statistical Methods. Survival rates were determined
using the Kaplan and Meier technique [22]. Event-free
survival (EFS) was deﬁned as time between diagnosis and
relapse or death from any cause. Overall survival (OS) was
deﬁned as time between diagnosis and death due to any
cause. Survival curves were compared between diﬀerent
groups using the log-rank test. Fisher’s Exact test was used
to compare categorical variables in univariate analysis using
SPSS v 17.0 (SPSS Inc, Chicago, IL).
3.Results
There were 87 adult and 15 pediatric patients (n = 102)
with a median follow-up time of 5.6 years (range 0.26–
18 years). The median age for adult and pediatric patients
was 37.6 (range 15 to 76) and 14 (range 0.4 to 18) years,
respectively. There were 5 patients less than age 18 (15,
16, 17 years) who were treated at the adult center and are
therefore included in the adult cohort. The most common
site for the primary tumor for all patients was the lower
extremity (n = 58, 57%). Sixty-ﬁve (64%) patients had
large tumors (≥5cm), 10 (9.8%) had bone invasion, and
6 (5.9%) had evidence of neurovascular invasion. (Table 1)
All tumours were high grade. All patients underwent en
bloc surgical resection resulting in 94 (92.2%) negative and
8 (7.8%) microscopically positive surgical margins. Twelve
(13.8%) ofadult patients had primary amputation—8 below
knee, 2 forequarters, 1 below elbow, and 1 above knee.
Seventy-two (82.8%) adult and 8 (53%) pediatric patients
received radiotherapy. The median radiation doses were
50.4Gy (range 50 to 66) for adult and pediatric patients.
Chemotherapy was administered to 25 (24.5%) patients,
12 (13.8%) adult and 13 (87%) pediatric. The median
number of chemotherapy cycles delivered was 5 and 7, for
adult,andpediatric patients,respectively.The mostcommon
chemotherapeutic regimen administered was doxorubicin-
based in 22 patients. The median total dose of doxorubicin
was 300mg/m2 (range 150 to 375) and 265mg/m2(range
90 to 375) for adult and pediatric patients, respectively
(target dose per cycle 75mg/m2). The median total dose
of ifosfamide was 25050mg/m2 and 23260mg/m2 for adult
(n = 9) and pediatric (n = 13) patients, respectively (target
dose per cycle 5g/m2). (Table 2)N i n e( 7 5 % )a d u l t sa n d1 0
(77%) pediatric patients received both anthracycline and an
alkylating agent. Among 12 adult patients who received neo-
adjuvantchemotherapy,response wasevaluatedin10.Aftera
median of 3 cycles of preoperative chemotherapy, there were
8 patients with stable disease, 1 partial response, and 1 case
with progressive disease, for a response rate of 10%. Five of
thirteen pediatric patients had repeat imaging after a median
of 2 cycles of chemotherapy. Response evaluated included 2
cases of stable disease, 1 partial response PR, 1 progressive
disease, and 1 complete response, for a response rate of 40%.
The estimated 5-year event-free survival (EFS) and
overall survival (OS) for the entire group were 69.3±4.8%
and 80.3±4.3%, respectively. The 5-year EFS for adult and
pediatricpatientswas68.3±5.2%and74.9±13%(P = .33),
respectively. The 5-year OS for adult and pediatric patients
was 76.9±5.0% and 100±27.2% (P = .36), respectively.
Disease relapse occurredin32(31.4%)patients(29/87adults
and 3/15 children): 28 (27.4%) had a distant recurrence in
the lung, 3 (2.9%) had a local recurrence, and 1 (1.0%)Sarcoma 3
Table 1: Patients and tumor characteristics.
Characteristic Adult
center (%)
Pediatric
center (%) Total (%) P
Age .0003
≤5 years 0 (0) 2 (13.3) 2 (2.0)
6–17 years 5 (5.7) 12 (80) 17 (16.7)
18–40 years 44 (50.6) 1 (6.7) 45 (44.1)
>40 years 38 (43.7) 0 (0) 38 (37.2)
Gender .16
Female 42 (48.3) 4 (26.7) 46 (45)
Male 45 (51.7) 11 (73.3) 56 (55)
Tumour size .5
<5cm 31 (35.6) 4 (26.7) 35 (34.3)
≥5cm 56 (64.4) 9 (60) 65 (63.7)
unknown 0 2 (13.3) 2 (2.0)
Depth .69
Superﬁcial 11 (12.6) 1 (6.7) 12 (11.8)
Deep 75 (86.2) 14 93.3) 89 (87.2)
Unknown 1 (1.1) 0 (0) 1 (1%)
Site .0001
Upper extremity 26 (29.9) 2 (13.3) 28 (27.4)
Lower extremity 53 (60.1) 5 (33.3) 58 (56.9)
Pelvic 0 (0) 1 (6.7) 1 (1)
Shoulder 0 (0) 1 (6.7) 1 (1)
Other 8 (92) 6 (40) 14 (13.7)
Margins .85
Negative 80 (92.0) 14 (93.3) 94 (92.2)
Microscopic
positive 7 (8.0) 1 (6.7) 8 (7.8)
Bone invasion .2
Present 10 (11.5) 0 (0) 10 (9.8)
Absent 65 (74.7) 15 (100) 80 (78.4)
Unknown 12 (13.8) 0 (0) 12 (11.8)
Neurovascular
Invasion .58
Present 6 (6.9) 0 (0) 6 (5.9)
Absent 69 (79.3) 15 (100) 84 (82.3)
Unknown 12 (13.8) 0 (0) 12 (11.8)
Radiation therapy .01
Yes 72 (82.8) 8 (53.3) 80 (78.4)
No 14 (16.1) 7 (46.7) 21 (20.6)
Unknown 1 (1.1) 0 (0) 1(1)
Chemotherapy .0004
Yes 12 (13.8) 13 (86.7) 25 (24.5)
No 75 (86.2) 2 (13.3) 77 (75.5)
developed concurrent local and distant relapse. The overall
rate of local disease recurrence was 4/102 (3.9%).
Patients with large tumors had signiﬁcantly worse EFS
(61.5±6.4%) compared to patients with smaller lesions
(81.9±6.7%, P = .03), and this was almost entirely related
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Figure 1: Event-free survival of all patients who did and did not
receive chemotherapy. blue line—no chemotherapy; Green line—
with chemotherapy.
todistant metastasis. (Table 3)Thepresenceofboneinvasion
was also associated with worse EFS (45±17.4% versus
74.5±5.1%, P = .02). The presence of neurovascular inva-
sion was not associated with worse EFS (60±21.9% versus
71.5±5.2%, P = .84). The eﬀect of chemotherapy was
initially assessed in the entire cohort. Of the patients who
received chemotherapy, 9/25 (36%) relapsed (3/13 children
and 6/12 adults) compared to 23/77 (30%; all adults) for
patients who did not receive chemotherapy. 5-year EFS
was similar in patients who received or did not receive
chemotherapy (62.6±11.2% versus 71.5±5.3%) (Figure 1).
In patients with tumors ≥5cm in whom chemotherapy
might be considered most appropriate, relapse occurred in
9/19 (47%) of those who received chemotherapy compared
to 17/46 (37%) in those who did not receive chemotherapy.
Event-free survival was not signiﬁcantly diﬀerent between
these 2 groups (P = .37). Margin status, depth, radiation
therapydidnotinﬂuenceEFS.TherewasnodiﬀerenceinEFS
between patients treated at the adult versus pediatric center,
or between those greater or less than age 18 orbetween those
greater or less than age 30, irrespective of treating hospital.
4.Discussion
In the setting of an adult and pediatric tertiary care center,
each with expertise in sarcoma management, the overall and
event-free survival rates for 102 patients with localized SS
were 80% and 69%, respectively, with no diﬀerence between4 Sarcoma
Table 2: Total cumulative dose of chemotherapy received.
Adult center Pediatric center
Median (range) Median (range)
mg/m2 n mg/m2 n
Chemotherapy
Doxorubicin 300 (150–375) 12 265 (90 – 375) 10
Ifosfamide 25050 (15030–39800) 9 23260 (7500–65600) 13
Cyclophosphamide 14590 (5180–24000) 2 4980 (1200–15260) 10
Table 3: Univariate analysis of prognostic factors in adult and
pediatric SS.
Variable 5-year EFS nP
Size <5cm 62±6.3% 35 .03
≥5cm 82±6.7% 65
Depth Superﬁcial 81.8±11.6% 12 .35
Deep 69.1±5.1% 89
Microscopic margin status Positive 62.5±17.1% 94 .62
Negative 70.4±5.0% 8
Center Pediatric 74.9±13.0% 15 .31
Adult 68.7±5.1% 87
Age
≤30 70.9±6.7% 51 .47
>30 68.6±6.8% 51
Bone invasion Present 45±17.4% 10 .02
Absent 74.5±5.1% 80
Neurovascular invasion Present 60.0±21.9% 6 .87
Absent 71.8±5.2% 84
Radiation Yes 69.6±5.4% 80 .67
No 67.5±11% 21
Chemotherapy Yes 62.6±11.2% 25 .48
No 71.5±5.3% 77
Adults Chemotherapy 56.3±14.8% 12 .13
No chemo 70.7±5.4% 75
Pediatric Chemotherapy 69.2±15.6% 13 .41
No chemo 100% 2
>5cm Chemotherapy 51.3±13.4% 19 .37
No chemo 65.7±7.2% 46
pediatric and adult patients, nor between those who did or
did not receive chemotherapy. Our data failed to demon-
strate that pediatric patients with localized SS have a better
outcome than adults or that routine use of chemotherapy
is beneﬁcial in reducing systemic relapse, even in patients
with large tumours. Although our ﬁndings are limited by
the nonrandomized delivery of chemotherapy and the small
sample size, this study contributes to the growing literature
questioning the routine use of chemotherapy in localized SS
[15, 16, 18, 23, 24].
Much of the current support for using chemotherapy
as part of the curative treatment protocol for management
of patients with localized but high-risk soft tissue sarcoma
arose following a randomized study by Frustaci et al. [25].
Unfortunately, the early promising results showing an
improvement in overall survival following treatment with
chemotherapy did not hold up with longer followup
[26]. A recent meta-analysis of chemotherapy in STS did
identify a marginal beneﬁt of doxorubicin and ifosfamide
treatment [27], although histologic subtype analyses were
not performed. However, other studies speciﬁc to SS have
continued to support a role for chemotherapy. Widemann
et al. reported 5-year metastasis-free survival rates of 60%
compared to 48% for those patients with localized SS who
did or did not receive chemotherapy, respectively, although
no statistical analysis was provided [28]. However, there
was no diﬀerence in overall survival rates between the two
treatment arms in that study. Eilber et al. reported a 4-year
distant relapse-free survival rate of 74% versus 46% (P =
.01), and disease-speciﬁc survival of 88% compared to 67%
in patients with SS treated with or without ifosfamide-based
chemotherapy, respectively [14]. However, it is interesting to
note that in our study, the 5-year overall survival of adults
who did not receive chemotherapy (75.6%) was comparable
to the chemotherapy treatment arms in these two studies.
Patients with SS are reported to have late relapses (after 6
years) [13], an event which would not have been uniformly
captured in our series.
In comparison to the above results, other studies have
refuted the role of systemic therapy for SS. A study of
237 patients from the French Sarcoma Group found that
chemotherapy had no signiﬁcant impact on outcome [15].
An analysis of 250 patients with SS treated at the Rizzoli
Institute also failed to show any improvement in survival
with chemotherapy, even using high doses of alkylating
agents (e.g., ifosfamide 9g/m2/cycle) [17, 23]. In our study,
adult patients received a median total cumulative dose of
ifosfamide of 25g/m2or just over 5g/m2 p e rc y c l ef o r5
cycles. Although there are reports of patients with metastatic
SS responding to even higher doses of ifosfamide (e.g.,
14g/m2/cycle) [29], this strategy has not been shown to
improve survival [30, 31].
Compared to other STS, SS has been considered a “more
chemosensitive” subtype as previous studies have docu-
mentedfavorableresponseratestochemotherapy[28,32].In
our study, the response rate to neo-adjuvant chemotherapy
was disappointing, particularly in adults. In comparison, the
40%responseratetochemotherapyobservedinthepediatric
patientsinourserieswascomparabletopreviouslypublished
reports of 37% [5] and 56% [19], but did not translate
into a survival advantage, similar to our adult group. OurSarcoma 5
evaluation of response to therapy was imperfect due to the
diﬀering number ofcyclesadministered to each patient prior
to radiological re-evaluation. Furthermore, there may be
limitations in using RECIST to evaluate response to therapy
in STS [33–36].
The 5-year EFS of 75% for children in our series is
comparable to rates of 74.3% [12] and 72% [5]r e p o r t e d
by others. The chemotherapy regimens delivered in these
pediatric series were variable, although the total cumulative
doses of ifosfamide and doxorubicin were similar to the
adult and pediatric patients of our study. Although the
majority of pediatric protocolscurrently oﬀerchemotherapy
f o rS S ,t h e r ei sal a c ko fp r o v e nb e n e ﬁ tf o rt h i sa p p r o a c h
[4, 5]. For example, in one large series, the 5-year EFS for
pediatric patients with localized SS, all of whom received
chemotherapy, was 41%, compared to 61% for all patients
(adult + children) in our study [6].
We report a very low local failure rate of 3.9% (4/102)
compared to other large studies which reported local recur-
rence in 18% [23], 23.5% [15], and 28% [28]o fp a t i e n t s
with localized and resectable SS. This is likely due to the
combination of a high rate of negative surgical margins
(92%), as well as the fact that the majority of adults and
approximately half the pediatric patients in our study were
treated with radiotherapy in a specialized sarcoma setting by
only a small number of radiation oncologists, which seems
to have a bearing on local control rates [37, 38]. Although
neither margin nor RT status were associated with the risk of
systemic relapse in our study, this may have been due to the
small number of cases which did not receive radiation or had
positive resection margins. However, these two factors are
strongly correlated with the risk of local relapse [15, 23, 28].
Although the impact of local recurrence on development of
metastasis is controversial for STS, there is certainly support
foracausativeeﬀect[39–42].The lowlocalrecurrenceratein
thisstudy may partially explain our favourablesurvival rates.
We identiﬁed tumour size as the most important pre-
dictor of systemic outcome, similar to almost every other
investigation of prognostic factors for SS. Patients with bone
invasion were also found to have worse outcomes, similar
to the ﬁndings by both Ferguson et al., [43] and Panicek
et al., who showed that bone invasion, identiﬁed either
pathologicallyorbyMRimaging,respectively,wasassociated
with worse overall survival in STS [44]. In comparison,
Panicek et al. and Ghert et al. showed that vascular invasion
or encasement was not a signiﬁcant predictor of outcome in
soft tissue sarcoma [44, 45].
The results of this study show that a well-planned
local therapy regimen including wide surgical resection,
with or without radiotherapy as necessary, is eﬀective in
preventing local relapse of SS. Unfortunately, the addition
of chemotherapy did not lead to an improvement in the
rates of systemic recurrence. Our patients with localized SS
had a very good chance of curative treatment with surgery
and radiation alone, even if their tumours were large. Since
this was true for both adult and pediatric patients [4, 46],
it suggests that the treatment approach for the diﬀerent age
groups should converge, recognizing that in some instances,
particularly for pediatric patients, there may be a higher
risk of morbidity due to the potentially detrimental eﬀects
of radiation on skeletal growth. The short- and long-term
toxicities of chemotherapy must be weighed against the
morbidities associated with radical surgery, with or without
radiotherapy. The long-term eﬀects of alkylating agents are
most important in the younger pediatric cohort, in whom
fertility preservation is a challenge for prepubertal boys
[47, 48] and in whom the magnitude of anthracycline car-
diotoxicity is well documented [49]. Chemotherapy should
not be automatically oﬀered to adult or pediatric patients
with localized SS. Rather, investigators should continue to
strive to develop novel agents that may directly target the
pathways aﬀected by the SYT-SSX translocation and develop
more eﬀective techniques of delivering systemic therapy.
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